An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients
Launched by ASTRA USA · Aug 30, 2001
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following are excluded:
- • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
- • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic and/or hypertensive retinopathy.
- • Known allergy to foscarnet.
- • Recurrent episode of cytomegalovirus (CMV) retinitis.
- Concurrent Medication:
- Excluded:
- • Nephrotoxic drugs.
- Patients with the following are excluded:
- • Recurrent episode of cytomegalovirus (CMV) retinitis.
- • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).
- • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy.
- • Known allergy to foscarnet.
- Prior Medication:
- Excluded:
- • Ganciclovir for cytomegalovirus (CMV) retinitis.
- • Foscarnet for CMV retinitis.
- • Patients with AIDS as defined by the CDC with manifest first episode cytomegalovirus (CMV) retinitis, as identified by its characteristic ophthalmoscopic appearance and verified by fundus photography.
- • Patients must be able to give informed consent.
About Astra Usa
Astra USA, a subsidiary of AstraZeneca, is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines that address unmet medical needs across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. With a strong commitment to advancing healthcare, Astra USA leverages cutting-edge science and technology to deliver high-quality treatments and improve patient outcomes. The organization emphasizes collaboration with healthcare professionals, regulatory bodies, and patient communities to ensure the safety and efficacy of its clinical trials, ultimately striving to enhance the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials